Week 4 viral load predicts long-term suppression of hepatitis B virus DNA during antiviral therapy: improving hepatitis B treatment in the real world
Truong, Jennifer; Shadbolt, Bruce; Ooi, Marie; Chitturi, Shivakumar; Kaye, G; Farrell, Geoffrey; Teoh, Narcissus
Background: Entecavir and tenofovir potently suppress hepatitis B virus (HBV) replication so that serum HBV DNA levels <20 IU/mL can be achieved after 2 years. Despite this, inadequate suppression is reported in >20% of cases for unclear reasons. Aim: We tested whether 4-week viral load (VL) assessment could improve 96-week treatment outcome. Methods: Data on all chronic hepatitis B patients treated with entecavir or tenofovir between 2005 and 2014 were entered prospectively. Full data capture...[Show more]
|Collections||ANU Research Publications|
|Source:||Internal Medicine Journal|
|01_Truong_Week_4_viral_load_predicts_2017.pdf||491.54 kB||Adobe PDF||Request a copy|
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.
Updated: 17 November 2022/ Responsible Officer: University Librarian/ Page Contact: Library Systems & Web Coordinator